Depo-Provera / Meningioma Lawsuit Update (August 2026)

Depo-Provera Is One of the Fastest-Moving Mass Torts Open Right Now

Depo-Provera client acquisition is generating measurable ROI for plaintiff firms that entered the market before bellwether verdicts begin compressing inventory and driving up lead costs. The MDL is formed, causation science linking Depo-Provera to meningioma is peer-reviewed and published in the BMJ, and the eligible claimant pool remains largely uncontacted. Firms running disciplined intake programs now are building case inventory at acquisition costs that will not hold once the litigation matures.

The Litigation Landscape: What the MDL Status Means for Case Value and Timing

MDL 3140 is centralized in the Northern District of Florida before Judge M. Casey Rodgers. The MDL formed in mid-2024 and is currently in early discovery. As of now, there are more than 3,500 active plaintiffs filed, and the docket is growing quickly.

Bellwether selection is expected around 2026, with first trials projected for 2027. Pfizer has not made any settlement overtures. That matters for how you think about the investment timeline.

Early-stage MDLs follow a predictable pattern. Before bellwether trials, the science drives case value expectations but the market has not yet tested those numbers in front of a jury. The 2023 Traore study, published in the British Medical Journal, is the causation anchor here. It found a 5.6-fold increased risk of intracranial meningioma among long-term Depo-Provera users. That is a strong relative risk number for a pharmaceutical case, and it triggered regulatory action in France before the U.S. litigation even consolidated. Progestins are known to stimulate meningioma growth through progesterone receptors, so the biological mechanism is not speculative.

The practical implication for your firm: you are acquiring cases now that will likely resolve in the 2027 to 2029 timeframe depending on bellwether outcomes and settlement negotiations. Strongest cases involve five or more years of continuous use and a meningioma requiring surgery. Those cases carry materially higher value expectations than minimum-threshold cases. Your intake and inventory strategy should reflect that distinction from day one.

The pre-bellwether phase is always the best time to build inventory. Once trials begin and verdicts start printing, cost per lead rises, referral fees climb, and aggregators start competing harder for the same pool. The firms that signed cases at $800 to $1,200 in 2025 will look very smart in 2028.

The Claimant Pool: Is There Still Volume to Capture?

Depo-Provera has been one of the most widely used injectable contraceptives in the United States for decades. It is heavily utilized in Medicaid and Title X family planning programs, which means the user base skews toward underserved populations that are often harder to reach through traditional legal advertising channels. That geographic and demographic profile is important for media planning.

The addressable pool of potential claimants who used Depo-Provera for one or more years and received a meningioma diagnosis is estimated in the tens of thousands nationally. There is no geographic restriction on this tort. Every state is in play. However, concentration is higher in regions with strong Medicaid penetration and active Title X clinic networks.

With only around 3,500 plaintiffs filed as of mid-2025, the pool is nowhere near exhausted. Awareness among potential claimants is still low compared to where it will be in 12 to 18 months as the MDL progresses and media coverage increases. That gap between available claimants and current filings represents the acquisition opportunity. Firms that run consistent, well-targeted campaigns right now are capturing cases that would otherwise never connect the diagnosis to the drug.

Saturation is not yet a serious concern. This is not a tort where 40 firms are hammering the same zip codes with identical creative. There is room for well-run campaigns to generate real volume at reasonable costs before competition tightens the market.

Depo-Provera Client Acquisition Economics: What Firms Are Actually Paying

Advertising economics on a tort like this depend heavily on how tight your qualification criteria are and what channels you run. Here is a realistic picture based on where this tort sits in the market right now.

Cost per lead on Facebook and Meta platforms is currently running in the $50 to $150 range for well-built campaigns. That range reflects the fact that the tort is not yet heavily saturated, creative has not been beaten into the ground by competing advertisers, and the population of people who have both used Depo-Provera long-term and received a meningioma diagnosis is specific enough to allow tight targeting.

Cost per signed retainer, accounting for lead-to-sign conversion rates at intake, typically lands in the $800 to $1,800 range depending on firm intake efficiency and qualification thresholds. Firms with strong intake operations and fast follow-up convert at higher rates, which pulls the cost-per-case number down meaningfully.

Facebook and Instagram remain the primary acquisition channels for this tort. The demographic (women, typically 30 to 60, with long-term contraceptive use history) indexes well on Meta platforms. Connected TV and programmatic display can supplement reach, particularly for geographic markets where Meta alone does not saturate the addressable pool. Search intent is still relatively low for this tort, which means paid search is a secondary channel right now rather than a primary one.

Creative that converts focuses on the connection between the drug and the diagnosis, not on legal process or firm credentials. The most effective ads lead with the medical link, the Depo-Provera to meningioma connection, and invite women who recognize that combination to learn more. Simplicity wins. Complicated ads explaining MDL timelines or filing deadlines underperform in cold audiences.

At MTAA, we run Depo-Provera campaigns on a transparent cost-plus model: 100% of the ad spend goes to media, and we charge a flat 15% fee on top of that spend for full campaign management. No hidden markups, no inflated media rates. Across more than $250 million in managed ad spend for over 600 plaintiff firms across 100-plus torts, that model has consistently delivered better economics than agency structures that bundle costs inside inflated media rates. Depo-Provera client acquisition is a tort where that cost discipline matters, because firms building real case inventory need predictable unit economics from the start.

Intake and Qualification: How Firms Screen and Sign Cases That Hold Up

The intake screen for Depo-Provera cases is relatively straightforward, which helps conversion rates. The core qualification elements are: injectable Depo-Provera use for at least one year (five or more years is where the strongest cases concentrate), and a confirmed intracranial meningioma diagnosis. Diagnosis confirmation means MRI, CT scan, or surgical pathology. Cases where the meningioma required monitoring, medication, or surgery are the ones with real settlement value. Incidental findings that were never treated carry more risk.

Retainer flow should include a signed medical authorization at intake so records can be ordered immediately. The earlier you have imaging and pathology reports in the file, the faster you can assess case grade and prioritize your inventory. Firms that sit on unverified cases and wait until MDL deadlines to pull records end up with cases that fall out late, which kills unit economics.

Statute of limitations varies by state but is typically tied to the date of meningioma diagnosis or the date the claimant could reasonably have known about the Depo-Provera connection. With awareness still low in the general population, many cases involve diagnoses from several years ago. Screen for diagnosis date carefully and flag anything that may require a tolling argument before you sign.

Fast follow-up at intake is not optional. Lead response time is one of the single biggest variables in cost-per-signed-case. A lead contacted within five minutes of submission converts at a rate three to five times higher than a lead contacted an hour later. Build the process around that reality, whether through in-house intake staff, an after-hours call center, or AI-assisted intake tools. Firms using AI to handle initial screening and intake qualification are seeing real efficiency gains here, and it is worth evaluating those tools seriously if intake capacity is a bottleneck. There is a practical framework for doing exactly that in "A Lawyer's Guide to AI" if your firm is working through that build-versus-buy decision.

The Window Is Open: Make a Decision on Depo-Provera Client Acquisition Now

The economics of Depo-Provera client acquisition are as favorable as they are going to be. The MDL is active but pre-bellwether. The causation science is strong. The claimant pool is large and under-reached. Advertising costs have not yet been driven up by a crowded field of competitors. Firms that commit to a disciplined campaign in 2025 will build inventory at cost structures that will look very different once bellwether verdicts start moving the market in 2027. That is the window, and it is open right now.